RxDoctor Payments Data

Jesse Welter, DO

Orthopaedic Surgery · Hanover, PANPI 1437383502

Payments from drug & device makers

$7,372in general payments, 2019–2025

Across 53 payments — averaging $139.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$4K
  • Novus Surgical Solutions LLC$1K
  • Johnson & Johnson$1K
  • Stryker$684
  • Medical Device Business Services, Inc.$273
  • Novus Surgical Consultants$240
  • plus $359 from 3 others

What the payments were for

  • Travel & lodging$3,63449%
  • Food & beverage$2,53834%
  • Education$1,20016%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex26$3,538
Novus Surgical Solutions LLC1$1,200
Johnson & Johnson7$1,077
Stryker9$684
Medical Device Business Services, Inc.5$273
Novus Surgical Consultants2$240
UOC USA Inc1$212
Sanara Medtech Inc.1$81
Biocomposites Inc1$66

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,372 in reported general payments places this provider in the 60th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.

See all orthopaedic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$328,292
Medicare patients
661
Services billed
2,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$4,836
Oxycodone Hcl251$1,371
Gabapentin125$1,184
Diclofenac Sodium59$955
Celecoxib37$624
Meloxicam170$524
Prednisone143$450
Mupirocin57$349
Tizanidine Hcl25$202
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$196
Amoxicillin161$176
Cephalexin14$165
Methylprednisolone19$157
Baclofen29$106
Hydromorphone Hcl15$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,077$4,83611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.

Other orthopaedic surgery in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →